35
total announcements
COHANCE.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 14 Oct 2026
Market Cap
₹16,733 Cr
P/E (TTM)
160.2
P/E (Forward)
45.3
EPS (TTM)
₹2.73
52W Low
₹266.70
52W High
₹917.85
Dividend Yield
0.00%
Beta
0.62
Price / Book
4.3
Debt / Equity
9.9
Revenue (TTM)
₹2,142 Cr
Gross Margin
70.36%
Operating Margin
-11.46%
Cohance Lifesciences Limited
Cohance Lifesciences Limited has received Central Government approval for the appointment of Mr. Umang Vohra as Chairman and Group CEO of the company.
Cohance Lifesciences Limited
Cohance Lifesciences Limited has informed the Exchange about grant of Stock Options to certain eligible employees of the Company.
Cohance Lifesciences Limited
Cohance Lifesciences Limited has appointed Mr. Abhimanyu Ojha as its Chief Financial Officer, effective October 12, 2026.
Cohance Lifesciences Limited
Cohance Lifesciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30 September 2026.
Cohance Lifesciences Limited
Cohance Lifesciences Limited has informed the Exchange about ESG Rating by Crisil ESG Ratings & Analytics Limited, with a rating of 'Crisil ESG 61 (Strong)' and Core ESG Rating of 'Crisil Core ESG 67 (Strong)'
Cohance Lifesciences Limited
Cohance Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window will be closed for the Designated Persons and their immediate relatives from 1 October 2026 till 48 hours after the declaration of Unaudited Financial Results for the quarter and half year ending 30 September 2026.
Cohance Lifesciences Limited
Cohance Lifesciences Limited has informed the Exchange regarding 'Completion of USFDA Inspection' at its API manufacturing facility in Jaggaiahpet, Andhra Pradesh.
Cohance Lifesciences Limited
Cohance Lifesciences Limited has informed the Exchange about its investment in Compulsorily Convertible Preferred Stock of NJ Bio Inc., USA, up to an amount of USD 10 million.
Cohance Lifesciences Limited
Cohance Lifesciences Limited held its 8th Annual General Meeting on September 17, 2026, through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The meeting commenced at 04:00 p.m. (IST) and concluded at 5:21 p.m. (IST). The requisite quorum was present, and the meeting was called to order. The Chairman delivered his speech, and the members were informed about the Integrated Annual Report for the financial year 2025-26. The Statutory Auditors' Report and the Secretarial Auditor's Report do not contain any qualification, observation, or adverse remarks.
Cohance Lifesciences Limited
Cohance Lifesciences Limited has informed the Exchange about Schedule of Analysts/ Institutional Investors Meet, where the management will be attending JP Morgan India Conference in Mumbai and JP Morgan Roadshow in Hyderabad.
Cohance Lifesciences Limited
Cohance Lifesciences Limited has informed the Exchange about the completion of a USFDA inspection of its formulation (FDF) plant located at Shamshabad, Telangana. The inspection concluded with the issuance of a Form FDA 483 containing four observations, and the company has initiated corrective and preventive actions.
Cohance Lifesciences Limited
Cohance Lifesciences Limited has announced two proposed transactions to strengthen its Antibody-drug Conjugate (ADC) strategy: an additional investment of USD 13 million in NJ Bio and a controlling investment of USD 5 million in Aruka Bio.
Cohance Lifesciences Limited
Cohance Lifesciences Limited has informed the Exchange regarding Outcome of Committee Meeting held on September 03, 2026, where the Investment, Banking and Authorisations Committee (IBA Committee) has approved the acquisition of additional shares in NJ Bio and a controlling investment in Aruka Bio to strengthen its Antibody-drug Conjugate (ADC) strategy.
Cohance Lifesciences Limited
Cohance Lifesciences Limited has informed the Exchange about its schedule of meet for Analysts/ Institutional Investors, to be held on 1 September 2026 at Ashwamedh - Elara India Dialogue 2026 in Mumbai.
Cohance Lifesciences Limited
Cohance Lifesciences Limited has informed the Exchange about a copy of newspaper publication regarding the 8th Annual General Meeting and e-voting information.
Cohance Lifesciences Limited
Cohance Lifesciences Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as per SEBI regulations.
Cohance Lifesciences Limited
Cohance Lifesciences Limited has informed the Exchange about Integrated Annual Report 2026, which includes the company's financial performance, business responsibility, and sustainability report for the FY 2025-26.
Cohance Lifesciences Limited
Cohance Lifesciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on 17 September 2026.
Cohance Lifesciences Limited
Cohance Lifesciences Limited has informed the Exchange about the withdrawal of credit ratings assigned by CRISIL Ratings Limited due to non-cooperation from the company, with the ratings being migrated to 'Crisil BB/Stable/Crisil A4+ Issuer not cooperating'.
Cohance Lifesciences Limited
Cohance Lifesciences Limited has informed the Exchange about the transcript of the earnings conference call held on 05 August 2026.